Cassiopeia, our 18,700-square-foot facility, will be able to produce more than 100,000 patient doses of non-carrier-added lutetium-177 per year.
We stand apart from other fusion companies because we have commercialized fusion today and we are scaling our technology. During each of our four phases, we’re perfecting core competencies needed for commercially viable fusion, producing useful products, building shareholder value, and reinvesting in future growth.
Join us and be part of the solution.
.jpg)